Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort
Journal of Clinical Lipidology · 2026-09 · 20 (9) · 1933-1945
DOI: 10.1016/j.jacl.2026.07.033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von David León-Jiménez und 21 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Vascular Risk Unit, Hospital Universitario Virgen del Rocío, Seville, Spain (León-Jiménez). Electronic address: daleji7…. Hauptthemen laut MEDLINE: Dicarboxylic Acids, Fatty Acids. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Bempedoic acid (BA) is an oral adenosine triphosphate-citrate lyase inhibitor that reduces low-density lipoprotein cholesterol (LDL-C) and is particularly relevant in patients with statin intolerance. However, real-world evidence on its effectiveness and safety remains limited. OBJECTIVE: To assess the effectiveness, safety, and treatment persistence of BA in a multicenter Spanish real-world cohort. METHODS: This retrospective observational study included 814 patients treated with BA across 21 vascular risk units in Spain. Lipid and laboratory parameters were evaluated at baseline and after 3 months. Generalized mixed models were used to estimate adjusted marginal means and treatment effects. RESULTS: BA significantly reduced total cholesterol (207.4-167.8 mg/dL; -19.1%) and LDL-C (121.3-86.5 mg/dL; -28.8%) (both P < 0.001). Smaller reductions were observed for high-density lipoprotein cholesterol (-3.9%) and triglycerides (-2.4%), while high-sensitivity C-reactive protein decreased nonsignificantly (-13.7%; P = 0.102). Uric acid increased (+11.4%; P < 0.001). LDL-C reduction was consistent across subgroups, with greater absolute reductions in patients with statin intolerance (-43.2 vs -26.7 mg/dL; P for interaction = 0.046). Concomitant ezetimibe use was associated with numerically greater LDL-C reduction without significant interaction. Patients receiving proprotein convertase subtilisin/kexin type 9 inhibitors or inclisiran achieved lower LDL-C levels and greater reductions. The discontinuation rate was 4.18%, mainly because of gastrointestinal symptoms and myalgias. CONCLUSION: In routine clinical practice, BA is an effective and generally well-tolerated lipid-lowering therapy, particularly in patients with statin intolerance or requiring combination treatment. These findings support its use as an effective lipid-lowering option in patients with statin intolerance or requiring combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Vascular Risk Unit, Hospital Universitario Virgen del Rocío, Seville, Spain (León-Jiménez). Electronic address: daleji73@gmail.com.
- Department of Endocrinology and Nutrition, Hospital Clínico Universitario of Valencia, Valencia, Spain (Martínez-Hervás); Department of Medicine, University of Valencia, Valencia, Spain (Martínez-Hervás); Biomedical Res…
- Internal Medicine Department, Vascular Risk Clinic, Hospital Universitario Severo Ochoa, Madrid, Spain (Lois-Martínez).
- Internal Medicine Department, Vascular Risk Area, Hospital Universitari Moisès Broggi, Barcelona, Spain (Jericó-Alba).
- Complejo Hospitalario de Jaén, Jaén, Spain (Martínez-Soriano).
- Althaia Xarxa Assistencial Universitària de Manresa, Barcelona, Spain (Complejo Hospitalario de Jaén).
Zitieren
APA
León-Jiménez, D., Martínez-Hervás, S., Lois-Martínez, N., Jericó-Alba, C., Martínez-Soriano, M. J., Royuela-Juncadella, M., Franco-Moreno, A., Rodríguez-Carnero, G., Varona, J. F., Muela-Molinero, A., García-Alonso, R., Castiella-Herrero, J., Cainzos-Achirica, M., Ramos, A., Gutiérrez-Lara, G., Miramontes-González, J. P., Luque-Linero, P., Vázquez-Ronda, M. Á., Torres-Do-Rego, A., …, & Rivas network, Spanish Society of Internal Medicine. (2026). Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort. Journal of Clinical Lipidology, 20(9), 1933-1945. https://doi.org/10.1016/j.jacl.2026.07.033
Vancouver
León-Jiménez D, Martínez-Hervás S, Lois-Martínez N, Jericó-Alba C, Martínez-Soriano MJ, Royuela-Juncadella M, et al. Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort. Journal of Clinical Lipidology. 2026;20(9):1933-1945. doi:10.1016/j.jacl.2026.07.033
BibTeX
@article{LenJimnez2026,
author = {León-Jiménez, David and Martínez-Hervás, Sergio and Lois-Martínez, Nagore and Jericó-Alba, Carlos and Martínez-Soriano, María Jesús and Royuela-Juncadella, Meritxell and Franco-Moreno, Anabel and Rodríguez-Carnero, Gemma and Varona, José F and Muela-Molinero, Alberto and García-Alonso, Rocío and Castiella-Herrero, Jesús and Cainzos-Achirica, Miguel and Ramos, Analía and Gutiérrez-Lara, Gema and Miramontes-González, José Pablo and Luque-Linero, Paula and Vázquez-Ronda, Miguel Ángel and Torres-Do-Rego, Ana and González-Bustos, Pablo and Puig-Jové, Carlos and Rivas network, Spanish Society of Internal Medicine., Rivas network, Spanish Society of Internal Medicine.},
title = {Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {9},
pages = {1933--1945},
doi = {10.1016/j.jacl.2026.07.033}
}
EUVIMED